Emily Estrada

According to results from a phase 3 trial, trastuzumab rezetecan significantly improved survival and response in chemotherapy-refractory HER2-positive advanced colorectal cancer.

Results from a multicenter phase 2 study demonstrated that neoadjuvant lorlatinib induced high pathological response and enabled substantial conversion to surgery in advanced ALK-positive non-small cell lung cancer.

Updated results from the phase 3 CROWN study demonstrate that lorlatinib sustains long-term benefit in treatment-naïve patients with advanced ALK-positive non-small cell lung cancer.

Based on results from the phase 2 CADENZA trial, the FDA has approved pivekimab sunirine for adult patients with blastic plasmacytoid dendritic cell neoplasms.

Results from the phase 3 TQB2450-III-11 trial demonstrated that benmelstobart plus chemotherapy followed by maintenance benmelstobart, anlotinib, and

Results from the phase 3 CHIPRO trial demonstrated that chiauranib plus weekly paclitaxel significantly improved progression-free survival with manageable safety in platinum-resistant or refractory ovarian cancer.

Results from the phase 2 FLAME study demonstrate that osimertinib plus chemotherapy significantly improves PFS in patients with EGFR-mutated advanced non-small cell lung cancer who remain ctDNA-positive after 3 weeks of first-line osimertinib.

Results from the phase 3 REVOL858R trial demonstrated that erlotinib plus ramucirumab followed by osimertinib did not improve outcomes in patients with EGFR-mutated advanced NSCLC.

Ivonescimab plus chemotherapy significantly improved overall survival compared with tislelizumab plus chemotherapy in previously untreated advanced squamous non-small cell lung cancer.

Asandeutertinib significantly improved intracranial response rates and intracranial progression-free survival compared with osimertinib in patients